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Abstract: Depression is twice as frequent in patients with diabetes as in the general   population, 
and has a negative impact on self-care, adherence to treatment, and the general prognosis of diabe-
tes. This underscores the importance of screening all diabetic patients for depression and, if neces-
sary, treating it with an effective antidepressant drug in parallel with standard diabetes   treatment. 
In a recent study, a simple two-question screening tool was used to screen diabetic patients for 
comorbid depression. The effects of the serotonin and norepinephrine reuptake inhibitor antide-
pressant, milnacipran, on metabolic parameters and depressive   symptoms in 64 diabetic patients 
with comorbid depression detected by this screen were   studied. Patients received   milnacipran 
for 6 months, in addition to standard diabetes treatment with metformin. At the end of the study, 
72% of patients had responded to antidepressant treatment ($50% reduction of baseline Beck 
Depression Score). The proportion of patients with ,8% glycosylated hemoglobin HbA1c (a 
common indication in diabetes of the need for intensive therapeutic intervention) had decreased 
significantly from 46.6% at baseline to 6.9%. HbA1c, fasting blood glucose, body mass index, 
total and low-density lipoprotein cholesterol, and serum triglyceride levels were all significantly 
decreased in patients with an antidepressant response, but not in patients whose depressive 
symptoms had not responded to milnacipran.
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Introduction
Depression is common in patients with diabetes mellitus.1 The prevalence of depression 
(major and minor) in patients with type 2 diabetes is reported to be almost twice that of 
the general population, ie, 17.6% versus 9.8%, respectively.2 The relationship between 
comorbid depression and diabetes is complex (Figure 1) and the pathophysiology is 
still unclear. As with other severe chronic illnesses, psychologic factors associated 
with suffering and diminished quality of life related to diabetes may trigger or enhance 
depressive symptoms.3 There is evidence, however, to suggest that depression may, in 
many cases, precede diabetes and act as a causal factor for weight gain and subsequent 
development of diabetes.4 Approximately 80% of diabetic patients are overweight or 
obese, and a complex relationship exists between obesity and depression.5–7 Depression 
can be a precursor or aggravating factor in the development of obesity, but there is also 
evidence that obesity may lead to depression.8,9 The comorbidity of diabetes and depres-
sion is associated with a significantly increased risk of death from all causes, beyond 
risks inherent with diabetes or depression alone.10–12 There appears to be a clear syn-
ergistic interaction between diabetes and depression,   resulting in decreased metabolic 
control, a higher incidence of vascular complications, and decreased quality of life in Neuropsychiatric Disease and Treatment 2010:6(Suppl 1) submit your manuscript | www.dovepress.com
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Diabetes in depression
• Response rate to antidepressants   ↓
• Resistance to therapy ↑
• Relapses ↑
• Severity of depressive symptoms ↑ 
• Burden of the depressive disorder ↑
Depression in diabetes 
• Compliance ↓
• Hyperglycemia ↑
• Quality of  diabetes adjustment ↓
• HbA1c ↑
• Subsequent illness due to diabetes ↑
• Morbidity & mortality for cardiovascular diseases ↑ 
• Quality of life ↓
• Health costs ↑
• Activity & function in daily living, performance ↓
• Burden/impairment by symptoms ↑
• Functional disability ↑
• Quality of life ↓
• CNS changes
• Complication rate ↑
Depression Diabetes
• Pathophysiological changes
• Higher expression of regulating hormones
• Disturbed transmembranous glucose transport
• Increased levels of proinflammatory cytokines
• Behavioral risk factors ↑
• Polypharmacotherapy ↑
Figure 1 Complex interactions between depression and diabetes. 
Modified from Regen et al.34
comorbid sufferers.1,10,13,14 Despite the importance of comor-
bid depression on the prognosis of diabetes,   diabetic patients 
are rarely screened for depressive symptoms, and depression 
frequently goes undetected and therefore untreated.
Treatment of comorbid depression 
in diabetic patients
If the presence of depression aggravates or precipitates 
  diabetes, what are the effects on diabetic symptoms of 
treating the depression with antidepressant medication? 
The impact of antidepressant therapy on metabolic and 
anthropometric parameters in diabetic patients with comorbid 
depression is still poorly understood.15–17
Studies with antidepressants have shown variable effects 
on metabolic control. In a study with sertraline, glycosylated 
hemoglobin (HbA1c) levels were reduced during   treatment, 
but did not differ between the sertraline and placebo 
groups,15,16 whereas no significant reduction in HbA1c levels 
was observed in patients treated with fluoxetine or   paroxetine, 
although their depressive symptoms were significantly 
improved.17 Similarly, although escitalopram resulted in a 
significant reduction of depression score, there was only a 
small and nonsignificant reduction in fasting blood glucose 
(FBG) levels and HbA1c levels.18 It would thus appear that 
selective serotonin reuptake inhibitors (SSRIs) do not have 
any major effect on metabolic control, even when they 
  produce a significant effect on depressive symptoms.
The expression of norepinephrine transporter mRNA has 
been shown to be decreased in the locus coeruleus and other 
brain regions in experimentally diabetic rats,19 suggesting a 
possible role for this neurotransmitter in the development of 
diabetes, especially in the case of comorbid depression where 
this monoamine is thought to be reduced.
A recent study20 has evaluated the effect of long-term 
treatment with the antidepressant, milnacipran, on depres-
sive symptoms and metabolic parameters in type 2   diabetic 
patients with comorbid depression. Milnacipran is a serotonin 
and norepinephrine reuptake inhibitor (SNRI)21 which inhibits Neuropsychiatric Disease and Treatment 2010:6(Suppl 1) submit your manuscript | www.dovepress.com
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the reuptake of the two monoamines with the most balanced 
potency ratio of all the SNRIs (1:1.6 for milnacipran; 
1:10 for duloxetine, and 1:30 for venlafaxine).22 Some studies 
have even shown that milnacipran inhibits norepinephrine 
uptake with greater potency than serotonin (2.22:1).23 It is 
thus the most noradrenergic of the SNRI antidepressants. In 
addition to being effective and well tolerated,21 milnacipran 
has a characteristic which makes it particularly attractive 
for treating diabetic patients with comorbid depression. It is 
one of the rare antidepressants that has no interaction with 
the cytochrome P450 enzyme system,24 and thus possesses 
a very low risk of drug-drug interactions. Because diabetic 
patients, especially those with comorbid depression, are likely 
to be treated with multiple medications, the risk of drug–drug 
interactions should be of constant concern.
This open-label longitudinal study20 was conducted in 
outpatients who fulfilled the criteria for type 2 diabetes mel-
litus as defined by the American Diabetes Association,25 and 
who had been screened positively for comorbid depression. 
Because diabetologists are not psychiatrists, it was necessary 
to find a simple way of screening diabetic patients for depres-
sive symptoms. A simple two-question screen, based on the 
questionnaire developed by Whooley et al26 was used:
Question 1. During the past month, have you often been 
bothered by feeling down, depressed, or hopeless?
Question 2. During the past month, have you often been 
bothered by little interest or pleasure in doing things?
A positive answer to both questions indicated the   probable 
presence of depressive symptoms. A diagnosis of depression 
was subsequently confirmed according to ICD-10 criteria for 
a depressive episode using the 12-item Major Depression 
Inventory (MDI) questionnaire.27
FBG, HbA1c, total cholesterol, LDL-cholesterol,   high-density 
lipoprotein (HDL)-cholesterol, serum   triglycerides, and weight 
were measured at baseline and after 6 months of treatment. 
Height was measured at baseline and was assumed to remain 
constant throughout the study. The severity of depression was 
measured at baseline and after 1, 3, and 6 months of treatment 
using the Beck Depression Inventory (BDI).28
All patients received standard diabetes treatment, 
ie,   metformin (500–2000 mg/day) as recommended by 
the Guidelines of the Austrian Diabetes Association.29 
  Milnacipran treatment was initiated at 25–50 mg/day, increas-
ing to 100 mg/day (50 mg twice daily) after a few days. Clini-
cians chose the initial dose and subsequent dose adjustments 
on the basis of the patient’s clinical response and tolerance 
of the drug.
Patients were generally obese, with a mean body mass 
index (BMI) of ,30 and with moderate to poor glycemic 
control (see Table 1). Of the 58 patients who completed the 
trial, 47% had a baseline HbA1c , 8%, usually   considered 
as an indicator of the need for intensive therapeutic 
intervention. The mean BDI score at baseline was 23.2, 
indicating a moderate to severe level of depression. Most 
of the patients (81%) had never taken antidiabetic drugs, 
their condition being managed by lifestyle adjustment only, 
and the majority (90%) had never taken   antidepressant 
medication.
BDI scores improved progressively during the study 
(Figure 2). After 6 months, nearly 72% of patients had 
responded to treatment (defined as a $50% decrease in base-
line BDI score). There was no difference between responders 
and nonresponders for age, severity of depression, metabolic 
control, or BMI at baseline.
Over the 6 months of the study, FBG levels, HbA1c, body 
weight, BMI, total cholesterol, LDL-cholesterol, and serum 
triglycerides were all significantly improved (Figure 3) and 
the proportion of patients with HbA1c , 8% decreased sig-
nificantly from 47% to 7%. Interestingly, this improvement 
in diabetic symptoms was principally due to reductions 
in patients with a response in their depressive symptoms. 
As shown in Figure 4, depression-responsive patients 
had significant improvements in all of the metabolic and 
anthropometric parameters studied, while nonresponders 
showed no significant improvements. Interestingly, there 
was a significant weight loss during treatment of these 
overweight or obese patients (Figure 5).
The contrast with the results of similar studies carried 
out with SSRIs is consistent with the importance of the 
role of noradrenergic neurotransmission which would 
Table 1 Metabolic parameters at baseline and after 6 months of 
treatment with milnacipran for all patients completing the study
Parameter Baseline Six months P
FBG (mg/dL) 155.0 113.0 ,0.0001
HbA1c (% of total Hb) 7.9 6.9 ,0.0001
Bodyweight (kg) 90.5 84 ,0.001
BMi (kg/m2) 30.4 28 ,0.001
Total chol (mg/dL) 199.5 178 ,0.0001
LDL-chol (mg/dL) 117 108 ,0.001
HDL-chol (mg/dL) 47.0 48.0 NS
Triglyc (mg/dL) 190 157 ,0.001
Note: All values are given as the median. P = significance of the difference between 
baseline and six-month values (paired t-test). 
Abbreviations:  HbA1c,  glycosylated  hemoglobin;  FBG,  fasting  blood  glucose; 
BMi, body mass index; total chol, total cholesterol; LDL-chol, low-density lipoprotein 
cholesterol;  HDL  chol,  high-density  lipoprotein  cholesterol;  Triglyc,  serum 
triglycerides; NS, not significant.Neuropsychiatric Disease and Treatment 2010:6(Suppl 1) submit your manuscript | www.dovepress.com
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be   stimulated by the inhibition of the norepinephrine 
transporter by milnacipran. Indeed, another study of a com-
pound with a marked noradrenergic component, bupropion, 
found that BMI and HbA1c levels decreased significantly 
during the acute   treatment phase with an association 
between   reduction of depression severity and reduction 
of HbA1c levels.30 Clearly, further studies are required to 
investigate the possible importance of the noradrenergic 
component of antidepressant action on metabolic param-
eters in diabetes.
Discussion
Despite the negative impact of untreated depression 
on diabetes care and prognosis,31,32 depression is still 
  underrecognized in diabetic patients. Diabetes is one of the 
most   psychologically and behaviorally demanding of the 
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Figure 3 Change in metabolic parameters during 6 months of milnacipran treatment. 
***P , 0.001 compared with baseline values. values are medians for all 58 patients who completed the study. 
Abbreviations: FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin; total chol, total cholesterol; triglyc, serum triglycerides.
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Figure 2 evolution of depression rating throughout the study. 
Note: The squares and single line refer to the depression rating as measured by the BDi (left hand axis). The gray columns refer to the percentage of patients responding 
to treatment ($50% decrease in baseline Beck Depression inventory score). values are medians for all 64 patients who started the study.Neuropsychiatric Disease and Treatment 2010:6(Suppl 1) submit your manuscript | www.dovepress.com
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Figure 4 Change in metabolic parameters in antidepressant responders and nonresponders during 6 months of milnacipran treatment. 
Note: Dark gray columns = antidepressant responders ($50% decrease in baseline BDi score, n = 46); light gray columns = antidepressant nonresponders, n = 12).   values 
are medians. 
*P , 0.05; ***P , 0.001 compared with baseline values. 
Abbreviations: FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin; total chol, total cholesterol; triglyc, serum triglycerides.
chronic medical illnesses. At least 90% of diabetes man-
agement is conducted by the patient himself or herself. The 
effect of comorbid depression on the patient’s motivation for 
self-care can result in unfavorable or even potentially fatal 
development of the disease.33 Although many physicians are 
aware of the importance of detecting comorbid depression in 
diabetic patients, many of them find it difficult to deal with 
in practice. Most diagnostic tools for screening depression 
are   complicated, time-consuming, or require at least some 
psychiatric training. The simple two-question screen used 
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Figure 5 Change of body weight in antidepressant responders during 6 months of milnacipran treatment. 
values are medians for all 46 patients who responded to the antidepressant and completed the study ($50% decrease in baseline Beck Depression inventory score). 
***P , 0.001 compared with baseline values.Neuropsychiatric Disease and Treatment 2010:6(Suppl 1) submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
14
Hofmann
in the above study was based on the two principal criteria of 
a depressive episode, ie, a period of at least 2 weeks   during 
which there is either depressed mood and/or the loss of inter-
est or pleasure in nearly all activities. A “no” response to both 
of the two questions means that depression is highly unlikely. 
For the rare patients who answer “yes” to only one of the 
questions, other symptoms should be elicited to confirm or 
refute a diagnosis of depression. Patients who reply positively 
to both questions are invariably depressed, and in the above 
study there were no “false positives”, ie, patients identified 
as possibly depressive who were subsequently found not to 
have a diagnosis of depression.
Once comorbid depression has been diagnosed in a 
diabetic patient it needs to be aggressively treated with an 
effective antidepressant. Although the demonstration is not 
yet definitive, the available evidence suggests that an anti-
depressant with a noradrenergic component is more likely 
to have a favorable impact on both diabetic and depressive 
symptoms.15–18 While SSRIs appear to be effective in treating 
depressive symptoms they seem to have little influence on 
diabetic symptoms in contrast with the SNRI, milnacipran,20 
and the catecholaminergic antidepressant, bupropion.29
As with all polymedicated patients, the physician 
needs to be particularly vigilant and wary of potential 
  drug-drug interactions. The use of an antidepressant such as 
  milnacipran, which has no interaction with any cytochrome 
P450 enzyme,24 reduces the risk of interactions.
Increasingly in modern medicine patient health is being 
seen as an integrated whole rather than as a collection of 
more or less independent complaints. The interaction between 
depression and diabetes, while still poorly understood, is 
extremely clear. Studies like the one illustrated here show 
that successful therapy of depression can have far reaching 
consequences for prognosis of diabetes and thus provide 
important global benefit for the patient.
Disclosure
The author is a consultant for Germania Pharmaceutika, who 
sell milnacipran in Austria.
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